Gene Therapy Research Institute starts manufacturing own vectors

The vectors are derived from adeno-associated virus (AAV), and the focus on application is on amyotrophic lateral sclerosis (ALS), aromatic amino acid decarboxylase (ADCC) deficiency. The onset of Parkinson’s disease will also be studied.

Nikkei Biotech news release, September 1, 2016

Most popular posts:

This website stores cookies on your computer. These cookies are used to provide a more personalized experience and to track your whereabouts around our website in compliance with the European General Data Protection Regulation. If you decide to to opt-out of any future tracking, a cookie will be setup in your browser to remember this choice for one year.

Accept or Deny